Products ({{ products.totalElements }})
News & articles ({{ wpNewsAndArticles.total_posts }})
Blog entries ({{ wpBlogEntries.total_posts }})

{{ String(product.attributes.name) }} {{ String(product.attributes.productType) }} - NEW	{{ String(product.attributes.artNo) }}	{{ (String(product.attributes.sizeStr) != 'undefined') ? String(product.attributes.sizeStr) : '–' }}	Not available On Request {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} {{ formatPrice(product.attributes.discountPrice.toString()) }} {{ formatPrice(product.attributes.price.toString()) }} Login for price

Full search results →

No products found

News {{ news.date \| formatDate }} #{{tag.name}}

No news & articles found

Full search results →

blog entry {{ blogEntry.date \| formatDate }}

No blog entries found

Full search results →

A-443654

Chemicals & Biochemicals

Make a customized order

Article No

AG-CR1-3663-M001

Size

1 mg

Shipping Information

Article No

AG-CR1-3663-M001

Size

1 mg

Specifications

CAS No	552325-16-3
MW	397.5
Article No	AG-CR1-3663-M001
Country Availability	SE, FI, DK, NO, IS, EE, LV, LT
Description	A-443654
Supplier	Adipogen Life Sciences
Format	Powder
Notes	Chemical. CAS: 552325-16-3. Formula: C24H23N5O. MW: 397.5. Synthetic. Potent and selective Akt inhibitor (Ki=160pmol/L for all three isoforms PKBalpha, PKBbeta and PKBgamma). DYRK1A inhibitor (IC50=10nM). Inhibits other kinases, including PRK2, MSK1 and DYRK3 at low nM range as well. Interferes with mitotic progression by regulating aurora a kinase expression and bipolar spindle formation. It induces G2/M accumulation, defects in centrosome separation and formation of either monopolar arrays or disorganized spindles. Anticancer agent. Apoptosis inducer and chemosensitizing agent. Slows the progression and growth of Akt-dependent tumors. Induces rapid Akt Ser473 phosphorylation independent of mTORC1 inhibition in human cancer cell lines. Activates mTORC2 and reverses long-term memory deficits.\|Potent and selective Akt inhibitor (Ki=160pmol/L for all three isoforms PKBalpha, PKBbeta and PKBgamma). DYRK1A inhibitor (IC50=10nM). Inhibits other kinases, including PRK2, MSK1 and DYRK3 at low nM range as well. Interferes with mitotic progression by regulating aurora a kinase expression and bipolar spindle formation. It induces G2/M accumulation, defects in centrosome separation and formation of either monopolar arrays or disorganized spindles. Anticancer agent. Apoptosis inducer and chemosensitizing agent. Slows the progression and growth of Akt-dependent tumors. Induces rapid Akt Ser473 phosphorylation independent of mTORC1 inhibition in human cancer cell lines. Activates mTORC2 and reverses long-term memory deficits.
Molecular Formula	C24H23N5O
Alias Names	(S)-1-(1H-Indol-3-yl)-3-((5-(3-methyl-1H-indazol-5-yl)pyridin-3-yl)oxy)propan-2-amine
Product Type	Chemicals & Biochemicals
Purity	>98%
Research area	Cell Death
Shipping Information	RT
Size	1 mg
Solubility	Soluble in DMSO (15mg/ml), ethanol (10mg/ml) or DMF (20mg/ml).
Stability	Stable for at least 2 years after receipt when stored at -20°C.
Storage	-20°C, 4°C
Technical Specifications	Chemical. CAS: 552325-16-3. Formula: C24H23N5O. MW: 397.5. Synthetic. Potent and selective Akt inhibitor (Ki=160pmol/L for all three isoforms PKBalpha, PKBbeta and PKBgamma). DYRK1A inhibitor (IC50=10nM). Inhibits other kinases, including PRK2, MSK1 and DYRK3 at low nM range as well. Interferes with mitotic progression by regulating aurora a kinase expression and bipolar spindle formation. It induces G2/M accumulation, defects in centrosome separation and formation of either monopolar arrays or disorganized spindles. Anticancer agent. Apoptosis inducer and chemosensitizing agent. Slows the progression and growth of Akt-dependent tumors. Induces rapid Akt Ser473 phosphorylation independent of mTORC1 inhibition in human cancer cell lines. Activates mTORC2 and reverses long-term memory deficits.
Product Page Updated	2024-02-01T08:25:01.492Z

Documentation

Datasheet

MSDS

References

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo: L. Luo, et al.; Mol. Cancer Ther. 4, 977 (2005) | Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition: E.K. Han, et al.; Oncogene 26, 5655 (2007) | A role for Akt in epidermal growth factor-stimulated cell cycle progression in cultured hepatocytes: generation of a hyperproliferative window after adenoviral expression of constitutively active Akt: Y. Luo, et al.; J. Pharmacol. Exp. Ther. 321, 884 (2007) | The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007) | Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia: F. Fala, et al.; Mol. Pharmacol. 74, 884 (2008) | Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression: X. Liu, et al.; Neoplasia 10, 828 (2008) | Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells: G.L. Gallia, et al.; Mol. Cancer Ther. 8, 386 (2009) | Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells: M. de Frias, et al.; Haematologica 94, 1698 (2009) | An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo: C. Cherrin, et al.; Cancer Biol. Ther. 9, 493 (2010) | Recent Advances in the Design, Synthesis, and Biological Evaluation of Selective DYRK1A Inhibitors: A New Avenue for a Disease Modifying Treatment of Alzheimer's: B. Smith, et al.; ACS Chem. Neurosci. 3, 857 (2012) | TORC2: a novel target for treating age-associated memory impairment: J.L. Johnson, et al.; Sci. Rep. 5, 15193 (2015)

Shipping info

The delivery time for this item is approximately 5-8 business days. Read more